The Indian Council of Medical Research (ICMR) and Panacea Biotec have launched the first-ever Phase 3 clinical trial for India's indigenous dengue vaccine, DengiAll, developed to combat all four dengue virus serotypes. This trial follows promising results from earlier phases and marks a significant step in enhancing India's vaccine research capabilities, as stated by Health Minister J.P. Nadda. Concurrently, Maharashtra has reported 88 hospitalizations due to the Zika virus, raising concerns over its transmission and potential congenital disabilities. As Zika cases rise, preventative measures against mosquito bites are emphasized, particularly for pregnant women. Additionally, the Qdenga dengue vaccine has shown over 50% efficacy in reducing dengue cases and eliciting strong immune responses, providing hope in dengue prevention efforts. The Indian government is also expediting the approval process for advanced foreign drugs and vaccines to improve patient access.